Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Can bilirubin nanomedicine become a hope for the management of COVID-19?

Isha Khurana a,1, Prince Allawadh ib,c,1, Amit Khurana c,d,f,g, Amit Kumar Srivastava b, Umashanker Navik c, Anil Kumar Banothu d,g, Kala Kumar Bharani f,g,*

a Department of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences (UIPS), Punjab University, Chandigarh 160014, India
b Department of Biotechnology, Indian Institute of Technology (IIT) Roorkee, Roorkee 247667, Uttarakhand, India
c Centre for Biomedical Engineering (CBME), Indian Institute of Technology (IIT) Delhi, New Delhi 110016, India
d Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science (CVSc), Rajender Nagar, Hyderabad 500030, PVNRTUV, Telangana, India
e Department of Pharmacology, School of Basic and Applied Sciences, Central University of Punjab, Bathinda 151001, Punjab, India
f Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science (CVSc), Warangal 506166, PVNRTUV, Telangana, India
g Department of Aquatic Animal Health Management, College of Fishery Science, Pebbair, Wanaparthy 509104, PVNRTUV, Telangana, India

ARTICLE INFO

Keywords:
COVID-19
Bilirubin
Biliverdin
Nanomedicine
Anti-inflammatory
Antioxidant

ABSTRACT

Bilirubin has been proven to possess significant anti-inflammatory, antioxidant and antiviral activities. Recently, it has been postulated as a metabolic hormone. Further, moderately higher levels of bilirubin are positively associated with reduced risk of cardiovascular diseases, diabetes, metabolic syndrome and obesity. However, due to poor solubility the therapeutic delivery of bilirubin remains a challenge. Nanotechnology offers unique advantages which may be exploited for improved delivery of bilirubin to the target organ with reduced risk of systemic toxicity. Herein, we postulate the use of intravenous administration or inhalational delivery of bilirubin nanomedicine (BNM) to combat systemic dysfunctions associated with COVID-19, owing to the remarkable preclinical efficacy and optimistic results of various clinical studies of bilirubin in non-communicable disorders. BNM may be used to harness the proven preclinical pharmacological efficacy of bilirubin against COVID-19 related systemic complications.

Introduction

SARS-CoV-2 pandemic is a global health challenge with no proven treatment regimens available. Current therapeutic strategies concentrate on the alleviation of symptoms, though to a lesser extent, emergency approved antiviral drugs and vaccines do provide relief [1]. However, treatment of this multifaceted disease, which poses severe complications in multiple organs, requires strategic attention to control viral load and simultaneously address other systemic complexities [2]. To this end, as a life-saving drug, corticosteroids like dexamethasone, which modulate the inflammatory microenvironment and reduce oxidative stress, have shown promising efficacy [3-5]. In such a scenario, it is imperative to demonstrate the clinical effectiveness of therapeutically active substances individually or in combination with other drugs having proven preclinical efficacy. Bilirubin possesses unique pharmacological effects, and its moderately higher levels have been shown to potentially reduce the risk of cardiovascular diseases (CVDs), diabetes, metabolic syndrome and obesity [6-10]. However, some controversial reports suggest that bilirubin plays a negative role in COVID-19, as bilirubin levels were found higher in a pool of such patients. However, this preliminary observation was due to systemic sepsis or viremia, further, no conclusive findings indicated any detrimental role of bilirubin in the clinical course of COVID-19 [11]. In previous studies, bilirubin as an endogenous antioxidant compound or its exogenous administration has demonstrated immense antioxidant, anti-inflammatory and immunomodulatory potential in various chronic diseases.
diseases [12,13]. Further, recently it was postulated as a metabolic hormone [14]. At the cellular and molecular levels, bilirubin reduces M1 macrophage polarization, expression of proinflammatory cytokines, improves gut barrier integrity, increases MHC-II, CD11c, CD11d dendritic cells (DCs), β-defensin-3, superoxide dismutase 1 and modulates molecular mechanism cascades relevant to pathogenesis of COVID-19 [15]. As the increased incidence and high mortality associated with COVID-19 has become a global burden and a grave challenge, there is still a great need for novel treatment options that can cure and ultimately eradicate this disease. This encourages us to propose the nanocarrier-mediated delivery of bilirubin that can be used as a potential alternative strategy to manage SARS-CoV-2 infection.

Hypothesis

We hypothesize that bilirubin nanomedicine (BNM) can be used as an alternative strategy for the management of COVID-19 by its property to halt the development of systemic inflammatory complications and cytokine storm by modulating the expression of transforming growth factor-beta (TGF-β), mitogen-activated protein kinase (MAPKs) and nuclear factor kappa light chain enhancer of activated B cells (NFκB) signaling pathways.

Justification of the hypothesis

Mechanism of pharmacological effects of bilirubin

Bilirubin has gained wide attention in biomedical research owing to its strong antioxidant, immunomodulatory and anti-inflammatory responses [16]. Moderately high serum bilirubin concentration protects against multiple clinical pathologies. In various preclinical studies, bilirubin at nanomolar concentrations showed potential pharmacological effects. Bilirubin elicits its anti-inflammatory and immunomodulatory activities by modulating the expression of NFκB, nuclear factor erythroid 2-related factor 2 (Nrf2), MAPK kinase, inducible nitric oxide synthase (iNOS) enzyme and reducing toll-like receptor 4 (TLR4) mediated inflammatory signaling pathways. Bilirubin possesses reactive oxygen species (ROS) scavenging activity, inflammatory cytokines inhibitory potential and the ability to restore physiological redox balance [17–19].

In the early 1970s, Nejedla reported that hyperbilirubinemia exerted a suppressive effect on antibody formation in newborn infants [20]. Later, it has been shown that intraperitoneal administration of bilirubin influences the expression of Fc receptors for immunoglobulin (Ig) M, IgG2B, IgA and IgE in immature mouse peritoneal macrophages via activating the tubulin system and altering the lipid environment of the plasma membrane [21]. Haga et al., reported that in human B lymphocytes, unconjugated bilirubin dose-dependently reduces the activity of class I antigens which activate cytotoxic T lymphocytes [22]. Similarly, in extended studies, bilirubin showed a protective effect in several autoimmune diseases, including encephalomyelitis through its broad spectrum suppressive effect on T cells reactivity and interference with NFκB [23,24]. Liu et al., reported that bilirubin inhibits the antigen-specific-polycytoplasmic T-cell response, suppresses CD4+ T-cell response and causes apoptosis in reactive CD4+ T cells at high doses. However, at non-apoptotic concentration, bilirubin suppressed CD4+ T-cell reactivity by inhibiting co-stimulatory activity, suppressing immune transcription factor activation, and downregulation of inducible MHC class II expression. Further, bilirubin treatment suppressed experimental autoimmune encephalomyelitis in SJL/J mice [24]. In addition, bilirubin showed an immunosuppressive effect by activating apoptosis via caspases 9 in lymphocytes, downregulation of protein kinase, and inhibiting MHC II class cell surface expression in molecules containing antigen presenting cells. Moreover, unconjugated bilirubin impairs the expression of Fc subsets, modulates the activity of macrophage and antigen-presenting cells through the upregulation of Fcγ1, Fcα, Fce, Fcox, and the downregulation of Fcγ2B receptors [25]. Altogether, bilirubin could have great potential to modulate the immune system.

Introduction to nanoformulations and potential of bilirubin as a nanomedicine against immune-mediated inflammation

Nanotechnology-based drug delivery systems are currently being used as a smart strategy to treat pathogenic infections due to their penetration ability across cell barriers owing to their smaller size and permeation into cellular compartments for site-specific drug delivery [21,26]. Among the different types of novel strategies, such as controlled release, sustained release or pH triggered/responsive release drug delivery systems, nanoparticles have attracted wide attention for intracellular delivery of drugs [27]. Nanoparticles offer distinctive physicochemical properties, such as high biocompatibility and negligible cellular toxicity in physiological systems [28]. Tailoring nanoparticles with bilirubin or other drugs may improve their therapeutic effectiveness by rapidly internalizing conjugated/encapsulated drugs into microbial cells through interactions with the negatively charged cell membrane [29]. These nanosystems offer excellent drug loading capacity, improved pharmacokinetics and minimal dose-related side effects. In addition, biocompatible polymeric materials such as chitosan with proven antimicrobial properties while polyesters and polyurethanes as bio-based polymers with aided antimicrobial properties offer a highly positive surface charge, which helps to transport drugs across the cell membrane [30].

The primary concern of COVID-19 is the diffuse alveolar epithelium damage resulting in lung injury and other cellular responses. Although the clinical course of molecular events and pathobiology of COVID-19 associated respiratory tract damage remains unknown. The primary pathophysiological mechanism for this is the triggered host innate immune response and subsequent accelerated inflammation caused by the cytokine constellation. Further, the condition may worsen when elevated cytokine levels promote lung fibrosis, making the disease almost incurable. DCs act as antigen-presenting cells (APCs) for coronavirus and display the virus on their surface on MHCII [31]. DCs migrate to the lymph nodes and activate allergen-specific T-cells that induce clonal selection and Th2 cells polarization. Th2 cells, in turn, produce cytokines (IL-13, IL-4 and IL-5) responsible for inflammatory and fibrotic reactions (Fig. 1). Bilirubin, a product of the enzyme heme oxygenase (HO-1) has strong antioxidant, anti-inflammatory and cytotoxic effects [32]. Over the last decades, several efforts were made to unravel the salient therapeutic features of bilirubin using a nanocarrier-mediated delivery system and overcome the limitations of its hydrophobicity and toxicity. Therefore, targeting the respiratory system with nano-based bilirubin delivery as an alternative therapeutic strategy to protect against coronavirus would be a plausible approach. BNMs have been reported to possess enhanced therapeutic effect as the volume-to-surface ratio significantly increases, which imparts bilirubin the improved catalytic properties [33]. Treatment of C57BL/6 mice with bilirubin-based nanoparticles suppressed experimental allergic asthma complications by modulating the expression of Th2 cytokines compared to untreated controls. Observed effect may be due to decreased T-cells population and their associated proinflammatory cytokines (IL-4, IL-5 and IL-13), via NFκB activation and co-stimulatory molecules of T cells in an antigen-presenting cell (APC)-independent way significantly attenuated Th2-related allergic lung inflammation. In addition, PEGylation of bilirubin into nanoparticles improved its pharmacokinetics and dispersibility compared to free bilirubin. This study showed bilirubin as an alternative nanomedicine to treat allergic pulmonary inflammatory diseases compared to currently available corticosteroids with potential side effects [34]. Fig. 2 depicts our postulated hypothesis for the probable mechanistic benefits of BNM. The high potency of bilirubin as an endogenous anti-inflammatory molecule makes it an attractive option for clinical implications. In a mouse model of dextran sodium sulfate-induced ulcerative colitis, unconjugated
Bilirubin treated animals showed reduced clinical severity of colitis and colonic tissue injury marked by restored intestinal mucosal barrier function and intestinal microbiota homeostasis. Furthermore, reduced immune inflammation was also characterized by significantly reduced levels of proinflammatory cytokines (IL-1\(\beta\), IL-6, IFN-\(\gamma\) and TNF-\(\alpha\)) through the alteration of different molecular signaling pathways (TLR4, TRAF6 and NF\(\kappa\)B) [18]. Bilirubin encapsulated silk fibroin-based nanoparticles (BRSNPs) were found to be highly biocompatible and protected pancreatic acinar cells from free radicals mediated oxidative damage and reduced the disease severity in rat acute pancreatitis model, evident by suppressed NF\(\kappa\)B and activated Nrf2/HO-1 pathway. This study showed the site-specific targeting capability of the synthesized BRSNPs demonstrated by the accumulation and internalization of BRSNPs into inflammatory pancreas. This study concluded the immense therapeutic potential of BNM with advantage of increased vascular permeability and retention of bilirubin in cellular and subcellular compartments through enhanced permeability and retention (EPR) effects. Such a bilirubin-functionalized nanocarrier-mediated delivery strategy can improve high payload of drugs, achieve controlled release of encapsulated drugs, and reduce the dose associated side effects [13,35]. Collectively, previous findings indicate that BNMs are highly effective against the prevention and management of various inflammatory diseases by harmonizing the inflammatory immune cells and levels of their related proinflammatory cytokines making them an interesting arsenal in the fight against COVID-19.

More recently, hyaluronic acid-bilirubin nanoparticles for inflammatory bowel diseases and doxorubicin-loaded-biotinylated bilirubin-nanoparticles, folate-gold-bilirubin nanoconjugate for cancer have been developed as BNM and found to be significantly effective [36–38]. The potential strategy to treat associated systemic infections and management of COVID-19 may be a combination drug delivery system that facilitates the easy transport of drugs to the target site. BNMs functionalized with biocompatible polymers would enhance cellular internalization of bilirubin due to interaction between nanoformulation and cell membrane resulting in membrane disruption and enhanced penetration, thus, providing a smart strategy to combat the threatening effects of COVID-19.

Potential of bilirubin nanomedicine (BNM) against cytokine storm

Cytokine storm is the most prominent cause, making COVID-19 pathology very complex and life-threatening [39,40]. Currently available medications have limited efficacy or elicit significant adverse effects, hampering their clinical use in COVID-19 management [41]. In this context, BNMs could be considered for their ability to restrain the cytokine signaling pathways like NF\(\kappa\)B, Janus kinases and signal transducer and activator of transcription proteins (JAK-STAT) etc. and halt the triggered expression and release of proinflammatory cytokines [42]. Administration of BNM to murine pancreatic islet allograft recipients extensively enhanced graft viability by alleviating cell apoptosis and reducing the expression of inflammatory cytokines such as IL-1\(\beta\), TNF-\(\alpha\), monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1) [43]. Similarly, BNM abrogated the severity of acute pancreatitis by dampening NF-\(\kappa\)B and TNF-\(\alpha\) expression and stimulating the Nrf2 activity [35]. Hyaluronic acid decorated BNM protected the experimental animals from dextran sulfate sodium...
induced colitis. Developed nanoformulation found accumulated in the inflamed colonic epithelium and restored the epithelium barriers integrity in the in vivo murine model of acute colitis by decreasing the expression of IL-1β, IL-6, IL-10, TNF-α and TGF-β [36].

Potential of BNM to fight against multiple organ dysfunctions

The clinical spectrum of COVID-19 is not limited to lung pneumonia; it also represents the multiple organ dysfunction and potential risk of other systemic complications [44]. Therapeutic intervention with bilirubin loaded nanoparticles has been shown to alleviate imiquimod (IMQ)-induced psoriasis in mice. Topical treatment of IMQ-induced psoriasis mice with BNM showed reduced clinical severity of psoriasis, downregulated ROS levels and decreased expression of proinflammatory chemical mediators. This study demonstrated BNM with high biocompatibility and reduced cellular toxicity for psoriasis management [45].

The anti-fibrotic effect of bilirubin conjugated chitosan nanoparticles loaded with losartan was investigated in a thioacetamide/ethanol-induced liver fibrosis mice model. Findings of the in vitro and in vivo experiments suggested that the ROS stimuli-responsive nanoparticles having losartan might be an appealing therapeutic choice to manage hepatic dysfunction and fibrosis [46,47]. Under strong antioxidant and anti-inflammatory potential, BNM reversed the typical characteristics of pancreatitis by inhibiting proinflammatory cytokines and restoring the altered levels of lipase and amylase. Moreover, BNM attenuated the expression of NFκB pathway, resulting in an overall improvement of the pancreas in L-arginine induced acute pancreatitis in mice [13,15]. Similarly, PEGylated BNM has been shown beneficial against allergen-induced allergic asthma by ameliorating Th2 mediated allergic lung inflammation confirmed by reduced Th2 cell population and related cytokines level [34].

Santangelo et al., demonstrated the virucidal effect of bilirubin against the enterovirus EV71 and human herpes simplex virus type 1 (HSV-1). Bilirubin-IX-α, at concentrations of 1–10 μM, close to those found in blood and tissues, significantly reduced the EV71 and HSV-1 replication in Vero and Hep-2 cell lines, respectively. Bilirubin-IX-α inhibited the viral infection of Vero cells and Hep-2 when given 2 h before and concomitantly after 2 h of the viral infection [6]. Similarly, biliverdin (BV) has been reported as a potent inhibitor of hepatitis C virus (HCV) NS3/4A protease, which exerts antiviral action against HCV by inducing dose-dependent activity of heme oxygenase-1. BV showed remarkable antiviral activity at concentrations as low as 20 μM. BV also augmented the antiviral activity of α-interferon in replicons. All these findings suggested that bilirubin and BV or its derivatives have potential antiviral activities which can also be investigated against the SARS-CoV-2.
Possible novel treatment strategies of bilirubin for COVID-19 therapeutics

Dosage form and route of drug administration to the patients remain key factors for an effective treatment strategy when using conventional or novel treatment options. The critical assessment of physicochemical and pre-formulation parameters is essential to develop a robust formulation that can deliver maximum therapeutic outcomes in patients [48]. To this end, nanotechnology and nanobiotechnology are providing innovative solutions [49]. Principally, COVID-19 causes significant damage to the lungs and renders them inefficient for routine function; therefore, pulmonary drug delivery must be incorporated as a therapeutic strategy for prominent action [50]. In this context, aerosol-based inhalation formulations might be a better approach which is not only patient compliant but can also exhibit the rapid relief over a defined period. In its free form, bilirubin has problems with its solubility; hence, its administration in nanoparticulate form offers enhanced solubility and improved efficacy. BNM as aerosol-based drug delivery system can deliver cargo directly to the lungs and reduce the complications of COVID-19 resulting in improved patient status. As the dose is required to be taken at short time intervals, it poses compliance issues. In such cases, BNM sustained release formulation can be administered directly through the intravenous route, which can provide 100% bioavailability and enhanced clinical response.

Bilirubin has unveiled encouraging effects in eliminating over-produced ROS and maintaining the cellular redox homeostasis; therefore, it is considered an efficacious therapeutic agent. Exogenous bilirubin also serves as an alternative for the shielding of heme oxygenase in various organs of the body. However, ample information regarding the toxic traits of bilirubin is present, such as neonatal hyperbilirubinemia and kernicterus [51,52]. In particular, the low solubility of bilirubin at physiological pH due to internal hydrogen bonds between the different polar groups is a hindrance to its intravenous administration. Several attempts have been made to overcome this limitation, such as binding bilirubin with glutathione-S-transferase, an intracellular protein or with albumin [53]. Kristin et al., demonstrated a protocol for intravenous administration of the exogenous bilirubin for its protective effects on ischemia-reperfusion induced injury in rats’ kidneys [54], where, bilirubin was added to a solution of pH 8 with the exception of albumin [55].

Moreover, it was suggested that upon intravenous administration, the protective effects of bilirubin have been observed to be model specific and organ specific. These effects may arise as a result of the variance in regional oxygen tension and microcirculatory hemodynamics of that particular organ, which plays climacteric role in the reperfusion phase that occurs instantly after a cardiac ischemic injury. Therefore, intravenous infusion of bilirubin was effective in prompt elevations of serum bilirubin concentrations, for a very short period of time. Besides, Nakao et al. have also observed the identical effects but were unable to produce these results in the kidney and heart in animal models [56]. Similarly, Clark et al., demonstrated similar effects in the isolated perfused rat heart model [57]. Hence, it delineates that various efforts have been made for intravenous administration of bilirubin to explore its

![Fig. 3. Administration of BNM by various routes and their advantages. Part of the figure were adapted and reproduced from reference [70] under the Creative Commons Attribution License (CCBY).](image-url)
usefulness as a therapeutic tool. Further, adding other treatment regimens in combination with BNMs would serve as a dual synergistic approach. Fig. 3 shows the proposed routes for BNMs administration.

Experimental strategy to test the hypothesis of bilirubin nanomedicine (BNM) as a potential candidate against COVID-19

The airway epithelial cells are located at the interface between the external and internal milieu and demonstrate a broad spectrum of activities associated with pulmonary inflammation, immune response, host defense and tissue remodeling. The airway epithelium plays a crucial role in the defense against various inhaled substances by modulating innate and adaptive immunity [58]. Moreover, airway epithelial cells show highly-expressed angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), as essential receptors for SARS-CoV-2 entry [59,60]. Further, experiments with SARS-CoV-2 infection using primary human airway epithelial cells have been found to demonstrate cytopathic effects 96 h after the infection [61]. Therefore, primary human airway epithelial cells can be utilized to test the potential anti-COVID-19 effects of BNM. Herein, we propose the following experimental design to investigate the effectiveness of BNM against COVID-19: group-I: control-bronchial primary human airway epithelial cells, group-II: bronchial primary human airway epithelial cells infected with SARS-CoV-2, group III: treatment of SARS-CoV-2 infected primary airway epithelial cells with various doses of BNM. Bronchial primary human airway epithelial cells can be maintained and cultured as earlier described by Vanderheiden et al. [62]. Infection in the bronchial primary human airway epithelial cells would trigger strong immune-mediated inflammatory cytokine response, while BNM treatment can reduce the cytokine storm and other proinflammatory chemical mediators.

In the case of COVID-19, where disease pathogenesis is complex and progressive, combination therapy is needed to cure or prevent further disease severity through a multidimensional mechanism of action. While proposing bilirubin as nanomedicine for the clinical management of COVID-19, which itself holds the therapeutic effects, the question arises how to design a safe and effective BNM rationally and effectively. We sincerely believe that this is a part at the end of both, i.e., clinical and formulation scientists. Therefore, when developing BNM, one should choose site-specific targeting to avoid the accumulation of free drug in healthy tissues and to enhance transportation across various biological barriers for improved drug bioactivity [63]. Further developed BNM should be characterized using state-of-the-art biophysical techniques for physiochemical analysis such as physical and surface properties, architectural composition and stability using standardized protocols [64]. Biocompatibility and comprehensive toxicity analysis of developed BNM choosing standard protocols and appropriate cell line based in vitro assay and the in vivo animal models following the guidelines of Organisation for Economic Co-operation and Development (OECD) for testing of chemicals are necessary, before its preclinical or clinical evaluation [65,66].

Until now, we know that the most prominent pathophysiological features of COVID-19 are upper respiratory tract infections that gradually lead to alveolar epithelial damage and chronic inflammation. In severe cases, when the virus severely attacks the immune system and modulates cellular and molecular homeostasis, it can cause systemic infection and life-threatening complications. Furthermore, there is a lack of understanding of the precise pathobiology and mechanistic molecular cascades involved in the pathogenesis of COVID-19. Now if we specifically focus on assessing the therapeutic effectiveness of BNMs developed for COVID-19, this can be done using clinically relevant cell lines based in vitro and in vivo animal models. In order to evaluate the altered expression of major cytokines relevant to COVID-19, an enzyme-linked immunosorbent assay (ELISA) may be performed on physiological fluid samples, or tissue homogenate of a particular organ, such as the lungs of the BNM treated experimental animals infected with SARS-CoV-2 [34]. In addition, intracellular cytokines staining with the aid of flow cytometry may also be performed. The tissue histopathological analysis can be performed to observe the major pathological changes in vital organs, such as lungs, kidneys and heart of the experimental animals. It is known that COVID-19 cause the upper respiratory tract collapse and bronchial inflammation, ROS generation assay using 5-(and-6)-chloromethyl-2,7-dichlorofluorescein diacetate (DCF-DA) staining and levels of proinflammatory cytokines and chemokines can also be analyzed using ELISA [34]. Further experiments such as quantitative polymerase chain reaction (qPCR) assay and indirect immunofluorescence assay (IFA) may be performed to analyze the inhibition of viral replication, its entry into the host cells and virucidal effect of BNMs [67,68].

Implications of the hypothesis

In conclusion, BNMs may provide a novel strategy for the pharmacotherapy of COVID-19 as it possesses not only antiviral efficacy but also anti-inflammatory and antioxidant effects. Further, it can be administered either systemically by intravenous route or locally to the lungs as an aerosol. Given that moderately higher serum levels of bilirubin have positive health benefits, the use of BNMs for COVID-19 management sounds appealing. Owing to the physiological relevance of bilirubin, BNMs may be excellent choice for effective management of this deadly viral infection.

Limitations and practical challenges in the implementation of proposed hypothesis

There is always the possibility of viral mutations and resistance development against the currently available medications, which may lose their effectiveness due to their specific response under different pathophysiological conditions. Therefore, evaluating effectiveness and safety and repurposing existing drugs are of utmost importance and should be considered a continuous process. For any new chemical entity or a drug molecule in the preclinical or clinical phase; it is crucial to determine its appropriate dosage form and route of administration to achieve maximum therapeutic response in patients. Since bilirubin is a hydrophilic molecule, it is susceptible to first-pass hepatic metabolism. This results in low systemic bioavailability of bilirubin and limits its clinical application as a drug candidate. Therefore, we propose the clinical use of bilirubin as a nanomedicine using appropriate drug delivery systems to overcome the limitations of poor solubility, sustained or controlled drug release and improved pharmacokinetics of bilirubin. Concurrently, nano-based drug delivery systems offer the advantage of high drug payload, smaller size and reduced dose associated side effects. Besides, it is necessary to identify a suitable route of administration for BNMs and a comprehensive toxicity assessment using clinically relevant animal models. There are significantly less data available on direct inhalation toxicological studies of different types of nanoparticles. The determination of the actual inhalation dose requirement is a daunting process which has restricted the specific designs of direct BNM inhalation formulations. Also, we are still a long way from deducing the nanotoxicological assessments in the relevant disease model [69]. Therefore, a comprehensive evaluation is needed before implementing the proposed hypothesis in the therapeutics of COVID-19.

Author contributions

JK, PA, AK, AKB, BKK- Conceptualization, Methodology, Writing-original draft. PA, AK, BKK- Writing - review and editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence
the work reported in this paper.

Acknowledgments

The authors would like to thank the Dean, Faculty of Veterinary Science, PV Narasimha Rao Telangana Veterinary University (PVNRTVU), Hyderabad, India.

References

[1] Oroojalian F, Haghibin A, Baradaran B, Heman N, Shahzad M-A, Baghi HB, et al. Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials. Int J Biol Macromol 2020.
[2] Contini C, Caselli E, Martini F, Maritati M, Torreggiani E, Seraceni S, et al. COVID-19 is a multifaceted challenging pandemic which needs urgent public health interventions. Microorganisms 2020;8(8):1228.
[3] Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone intervenes. J Immunol (Baltimore, Md.: 1950) 2008;181(3):1887.
[4] Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular clinical trials. Int J Biol Macromol 2020.
[5] Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. J Gastroenterol Hepatol 2020;35(6):622–4.
[6] Nakao A, Choi AMK, Murase N. Protective effect of carbon monoxide in ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol 1997;272(2):H643.
[7] Zahir F, Rabbani G, Khan RH, Rizvi SJ, Jamal MS, Abuzenadah AM. The nanomedicine platform of bilirubin: a historical perspective. J Photochem Photobiol B 2017;171:118–20.
[8] Bhatia D, Beirne SL, Strulovici-Barel Y, et al. A novel biocompatible biopolymer for targeted drug delivery: characterization of electrospun chitosan fibres. Mater Sci Eng C 2018;80:1–7.
[9] Yao Q, Sun R, Bao S, Chen R, Kou L. Bilirubin protects transplanted islets by modulating T cells. J Clin Invest 2008;118(11):3711–20.
[10] Hahm JS, Ostrow JD, Mukerjee P, Celic L. Ionization and self-association of unconjugated bilirubin. J Lipid Res 1992;33(8):1123–30.
[11] Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Ornelas J. Bilirubin nanomedicines for COVID-19. Nat Nanotechnol 2020;15(8):622–30.
[12] Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome. J Clin Pathol 2003;56(8):789–98.
[13] Djomkam ALZ, Olwal CO, Sala TB, Paemka L. Commentary: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. J Respir Crit Care Med 2020;202(2):219–29.
[14] Zhang H, Hestani MR, Leopold PL, Mezey JG, O’Byrne SJ, Sluiter-Silvasti B, et al. Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. J Respir Crit Care Med 2020;2(2):159–69.
[15] Hsieh PM, Hsiung SC, Liao YS, et al. In vivo imaging of pulmonary inflammation. J Photochem Photobiol B 2009;95(1):133–41.
[16] Kim JT, Lee DY, Kang S, Miao W, Kim H, Lee Y, et al. Bilirubin nanoparticles preconditioning protects against hepatic ischemia-reperfusion injury. Biomaterials 2017;133:1–10.
[17] Lee Y, Lee S, Jon S. Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug delivery system for targeted cancer therapy. Adv Sci 2018;5(6):1800017.
[18] Allawadhi P, Khurana A, Allwadhi S, Joshi K, Packirisamy G, Bharani KK. Nanoceria as a possible agent for the management of COVID-19. Nano Today 2020;35:100982–100982.
[19] Allawadhi P, Khurana A, Allwadhi S, Joshi K, Baradaran B, Hemat N, et al. Hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis 2020;11(7):512.
[20] Khurana A, Sayed N, Allawadhi P, Weiskirchen R. It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis. Ann Trans Med 2020.
[21] Arahjo J, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and athero-endothelial function. Front Immunol 2019;10:371.
[22] Sarkar S, Makhul A, Barabush S, Mahmood MA, Dutta J, Pel SK. Nanoparticle-sensitized photodegradation of bilirubin and potential therapeutic application. J Photochem Photobiol C 2012;11:908–15.
[23] Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee S-H. Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma. Biomaterials 2017;140:37–44.
[24] Kim MJ, Lee Y, Jon S, Lee DY. PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation. Biomaterials 2017;133:242–52.
[25] Lee Y, Sugihara K, Gilliland MG, Jon S, Kamada M, Nonaka T, Tsuchimoto T. Hydrophilic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater 2019;1–9.
[26] Rathinajaraj P, Muthusamy G, Prasad NR, Gunaseelan S, Kim B, Zhu S. Folate-gold-bilirubin nanocapsulate induces apoptotic death in multidrug-resistant oral carcinoma cells. Eur J Drug Metab Pharmacokin 2019:1–12.
[27] Lee Y, Lee S, Jon S. Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug delivery system for targeted cancer therapy. Adv Sci 2018;5(6):1800017.
[61] Takayama K. In vitro and animal models for SARS-CoV-2 research. Trends Pharmacol Sci 2020;41(8):513–7.

[62] Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S, et al. Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J Virol 2020;94(19).

[63] Yao Q, Chen R, Ganapathy V, Kou L. Therapeutic application and construction of bilirubin incorporated nanoparticles. J Control Release 2020.

[64] Lin P-C, Lin S, Wang PC, Sridhar R. Techniques for physicochemical characterization of nanomaterials. Biotechnol Adv 2014;32(4):711–26.

[65] Patel P, Shah J. Safety and toxicological considerations of nanomedicines: the future directions. Curr Clin Pharmacol 2017;12(2):73–82.

[66] Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem 2018;6:360.

[67] Ghaffari H, Tavakoli A, Mozaffi A, Tabarzadi A, Bakharazi-Salim F, Zahmatkeshan M, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci 2019;26(1):1–10.

[68] Medhi R, Srinoi P, Ngo N, Tran H-V, Lee TR. Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater 2020;3(9):8557–80.

[69] Saifi MA, Khurana A, Godugu C. Nanotoxicology: toxicity and risk assessment of nanomaterials. In: Nanomaterials in chromatography. Elsevier; 2018. p. 437–65.

[70] Orienti I, Gentilomi GA, Ferrugia G. Pulmonary delivery of fenretinide: a possible adjuvant treatment in COVID-19. Int J Mol Sci 2020;21(11):3812.